• NeuroNode distribution strategy advancing in North America
• NextLevel iOS speech device program and first LOI executed
• NeuroNode included in German Statutory Health Insurance Medical Aids Directory
• NeuroStrip commercial rollout progressing

Control Bionics Limited (ASX: CBL) announced its Quarterly Activities Report and Appendix 4C for the quarter ended 31 March 2026. The company continued to progress its transition to a distributor-led AAC model in North America, with onboarding and engagement of key partners. Control Bionics also entered into a strategic partnership with NextLevel Assistive Technology to commercialize iOS-based speech generating devices in the United States, executing its first Letter of Intent under the program. An important regulatory milestone was achieved with the inclusion of NeuroNode in the German Statutory Health Insurance Medical Aids Directory, enabling reimbursement eligibility and supporting expansion into the German and broader European markets. The company continued to advance the commercial rollout of its NeuroStrip platform, which is now in-market and being used in both the US and Australia across sports performance, rehabilitation and research settings. Cash receipts totaled $1.2 million for the quarter, with net operating cash outflows of $1.7 million, broadly consistent with the prior quarter.

The company remains focused on disciplined execution, continuing to progress its key strategic initiatives while managing costs and positioning the business for scalable growth. The company intends to provide a further update of its key strategic initiatives and positioning the business for scalable growth in May.